文献速递白血病造血干细胞移植与细胞治疗

接受异基因移植的急性髓系白血病患者中ELN2017风险分层的预后影响

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

该研究对234例接受异基因造血干细胞移植作为巩固治疗的急性髓系白血病患者按ELN2017分类进行风险分层,其中39.7%为预后良好、12.8%为中等、47.4%为不良。移植背景下三个风险组仍保留预后意义,单体核型或TP53突变患者即使归入不良风险组复发率仍显著增高,移植前MRD阳性患者预后与ELN2017不良遗传风险组相当。

要点

  • ELN2017分类在异基因移植后仍可区分三个预后显著不同的风险组。
  • 单体核型或TP53突变患者即使属不良风险组,复发率仍明显增高。
  • 移植前MRD阳性者复发累积发生率和总生存与ELN2017不良遗传风险组相当。

核心结论

  • 本研究首次证明ELN2017分类在异基因造血干细胞移植后仍能区分三个预后显著不同的风险组。
  • 研究强调携带TP53突变、单体核型或移植后MRD阳性的急性髓系白血病患者预后极差。

研究设计与样本

  • 对234例接受异基因造血干细胞移植作为巩固治疗的急性髓系白血病患者进行ELN2017风险分层。
  • 采用基于微滴式数字PCR的可测量残留病(MRD)检测移植前MRD状态。

主要发现

  • 队列中39.7%的患者被归为预后良好、12.8%为中等、47.4%为不良。
  • 异基因移植背景下三个ELN2017风险组仍保留预后意义,预后良好组预后最佳、不良风险组预后最差。
  • 亚组分析显示单体核型或TP53突变患者复发率明显增高,即使位于不良风险组内亦然。
  • 移植前MRD阳性患者预后受损,其复发累积发生率和总生存与ELN2017不良遗传风险组患者相当。

局限性

  • 原文指出在异基因造血干细胞移植背景下关于ELN2017风险分类预后意义的研究此前尚缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2017, an updated European LeukemiaNet (ELN) risk classification was published allocating patients with acute myeloid leukemia (AML) to 3 risk groups on the basis of certain cytogenetic and molecular aberrations. To date, studies of the prognostic significance of the ELN2017 risk classification in the context of an allogeneic hematopoietic stem cell transplantation (HSCT) are lacking. We performed risk stratification according to the ELN2017 classification in 234 patients with AML who underwent allogeneic HSCT as a consolidation therapy. In our cohort, the risk of 39.7% of the patients was classified as favorable, that of 12.8% as intermediate, and that of 47.4% as adverse. In the context of allogeneic HSCT, the assignment to the 3 ELN2017 risk groups retained its prognostic significance, with patients with favorable risk having the best prognosis and those with adverse risk having the worst one. Subgroup analyses showed that patients with a monosomal karyotype or TP53 mutation had considerably increased relapse rates, even in the adverse-risk group. When we analyzed the impact of digital droplet PCR-based measurable residual disease (MRD) before allogeneic HSCT, MRD+ patients had impaired prognoses, with cumulative incidence of relapse and overall survival comparable to those of patients classified as having an ELN2017 adverse genetic risk. This study is the first to demonstrate that the ELN2017 classification distinguishes the 3 risk groups with significantly distinct prognoses, even after allogeneic HSCT, and emphasizes the dismal prognosis of patients with AML with TP53 mutations, monosomal karyotype, or MRD positivity after allogeneic HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Grimm J, Jentzsch M, Bill M, et al. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv. 2020. PMID: 32810221. doi:10.1182/bloodadvances.2020001904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。